New study tracks how well lorviqua works outside the lab for advanced lung cancer
NCT ID NCT05599412
First seen Apr 10, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This study is observing 600 adults in Korea with ALK-positive metastatic non-small cell lung cancer who are taking the drug Lorviqua as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in everyday medical practice. The goal is to gather real-world safety and effectiveness data, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ALK+ NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.